Alpha 2.0
Login Register
» Authors » Niviann M Blondet

Niviann M Blondet

Explore the profile of Niviann M Blondet including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 24
Followers 0
Related Specialties
Pediatrics
Gastroenterology
Top 10 Co-Authors
Patrick J Healey
Jorge D Reyes
James D Perkins
Andre A S Dick
Paula Hertel
Marialena Mouzaki
Jeffrey B Schwimmer
Miriam B Vos
Jean P Molleston
Evelyn K Hsu
Published In
Pediatr Transplant
Semin Pediatr Surg
J Pediatr Gastroenterol Nutr
Liver Transpl
Hepatology
Affiliations
Soon will be listed here.
Recent Articles
1.
ABO Incompatible Grafts Are Associated With Excellent Outcomes in Pediatric Liver Transplant Recipients: An Important Resource to Reduce Waitlist Mortality
Valentino P, Healey P, Perkins J, Desai B, Quezada H, Blondet N, et al.
Pediatr Transplant . 2025 Mar; 29(3):e70047. PMID: 40051155
Background: Liver transplant (LT) waitlist mortality occurs in 10% of children; innovative strategies to expand access to LT can be lifesaving. Methods: Outcomes of ABO incompatible (ABOi) LT performed between...
2.
Outcomes of pediatric candidates for liver retransplantation in the modern era: Strategies are needed to avoid waitlist mortality in the United States
Valentino P, Blondet N, Perkins J, Hsu E, Saarela K, Wendel D, et al.
Liver Transpl . 2025 Jan; PMID: 39820209
Pediatric liver retransplantation (rLT) has historically shown poorer outcomes compared to primary liver transplantation (pLT). Comprehensive studies assessing outcomes for pediatric candidates for rLT under the modern allocation policy are...
3.
Renal impairment is prevalent in pediatric NAFLD/MASLD and associated with disease severity
Mouzaki M, Yates K, Arce-Clachar A, Behling C, Blondet N, Fishbein M, et al.
J Pediatr Gastroenterol Nutr . 2024 Jun; 79(2):238-249. PMID: 38828720
Objectives: Renal impairment is prevalent in adults with nonalcoholic fatty liver disease (NAFLD/metabolic dysfunction associated steatotic liver disease [MASLD]) and is associated with increased mortality. Pediatric data are limited. Our...
4.
Randomized placebo-controlled trial of losartan for pediatric NAFLD
Vos M, Van Natta M, Blondet N, Dasarathy S, Fishbein M, Hertel P, et al.
Hepatology . 2022 Feb; 76(2):429-444. PMID: 35133671
Background And Aims: To date, no pharmacotherapy exists for pediatric NAFLD. Losartan, an angiotensin II receptor blocker, has been proposed as a treatment due to its antifibrotic effects. Approach And...
5.
Do funding sources influence long-term patient survival in pediatric liver transplantation?
Dick A, Winstanley E, OHara M, Blondet N, Healey P, Perkins J, et al.
Pediatr Transplant . 2020 Oct; 25(2):e13887. PMID: 33112037
Background: Socioeconomic status has been associated with inferior outcomes after multiple surgical procedures, but has not been well studied with respect to pediatric liver transplantation. This study evaluated the impact...
6.
The impact of public health service increased risk donors in pediatric liver transplantation
Dick A, Blondet N, Shaw K, Healey P, Horslen S, Smith J, et al.
Pediatr Transplant . 2020 Apr; 24(4):e13712. PMID: 32320115
Many transplant programs are reluctant to use organs from deceased donors designated as "PHS increased risk" due to misconceptions regarding the quality of those organs. This study evaluated the impact...
7.
Immunosuppression in the pediatric transplant recipient
Blondet N, Healey P, Hsu E
Semin Pediatr Surg . 2017 Oct; 26(4):193-198. PMID: 28964473
The field of pediatric solid-organ transplantation has significantly evolved since its beginnings in the early 20 century. As advancements have led to the development of innovative surgical techniques and novel...